Page 177 - Eceptor News Today

A new study assessed nAb activities against five strains of SARS-CoV-2 in paired maternal and infant cord blood samples.

Scientists identified a human monoclonal antibody (mAb), which successfully neutralized or bound all sarbecoviruses tested in vitro.

V-SYNTHES is a new computational method for analyzing billions of theoretical compounds as candidates for therapeutic drugs.

A new study found that the Omicron S protein evades antibodies with a 44-fold higher efficiency than the Delta variant's spike, rendering therapeutic antibodies ineffective and likely negatively impacting antibody protection induced by infection or double vaccination.

A new study determines the ability of individuals with varying exposure to SARS-CoV-2 infection and vaccination, to neutralize SARS- CoV-2 pseudotypes.

A new study has used this assay to evaluate sera, obtained from 239 individuals vaccinated via any of the above-stated vaccines against SARS-CoV-2’s original strain, the Delta, and Omicron SARS-CoV-2 pseudoviruses.

A new study examined the neutralization of virus variants using three sets of antibodies: serum from individuals vaccinated or infected with earlier variants of the virus; concentrated human antibodies from plasma donors; and approved monoclonal antibodies.

The Lupus Research Alliance proudly announced today 11 research grant recipients in the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas from probing the development and progression of lupus to pointing to potential personalized therapies.

Researchers find that the SARS-CoV-2 Omicron variant shows a much more extensive escape from vaccine-elicited immunity.

An international research team co-led by scientists at Roswell Park Comprehensive Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified an important accelerator of treatment-resistant prostate cancer.